December 10th 2020, 11:45am
San Antonio Breast Cancer Symposium
Lee Schwartzberg, MD, FACP, chief medical director of West Cancer Center and chief medical officer of OneOncology, discusses the approvals of pembrolizumab and sacituzumab govitecan for patients with triple-negative breast cancer.
December 10th 2020, 2:45am
San Antonio Breast Cancer Symposium
During the San Antonio Breast Cancer Symposium 2020, Lajos Pusztai, MD, DPhil, of Yale Cancer Center, reviewed recently established and emerging biomarkers in both the neoadjuvant and metastatic breast cancer settings.
December 9th 2020, 9:00pm
San Antonio Breast Cancer Symposium
Yuan Yuan, MD, PhD, medical oncologist at City of Hope, discusses an ongoing study on ipatasertib with chemotherapy and atezolizumab presented at the San Antonio Breast Cancer Symposium 2020.
December 9th 2020, 2:00pm
San Antonio Breast Cancer Symposium
City of Hope's Joanne Mortimer, MD, a medical oncologist and director of the Women's Cancer Program, discusses a poster presentation from the 2020 San Antonio Breast Cancer Symposium.
December 9th 2020, 1:30pm
San Antonio Breast Cancer Symposium
A panel at the 2020 San Antonio Breast Cancer Symposium discussed 3 new drug approvals from the past year, highlighting changes in the treatment landscape across multiple breast cancer types.
December 8th 2020, 11:00pm
San Antonio Breast Cancer Symposium
Rachel Jimenez, MD, radiation oncologist at Massachusetts General Hospital, outlines the prevalence of cardiac toxicity, as well as the short-term and long-term impacts.
December 8th 2020, 9:15pm
San Antonio Breast Cancer Symposium
The first session at the San Antonio Breast Cancer Symposium 2020 looked at how the COVID-19 pandemic is disproportionately affecting care for minority patients.
December 8th 2020, 3:23pm
ASH: American Society of Hematology
As more data have become available, we are seeing more and more patients receiving chimeric antigen receptor (CAR) T-cell therapy in the community setting, noted Karl Kilgore, PhD, senior research scientist at Avalere Health.
December 8th 2020, 3:00pm
ASH: American Society of Hematology
A late-breaking study presented at the American Society of Hematology annual meeting raises the specter of whether interventions can occur decades before a blood cancer would appear.
December 8th 2020, 4:45am
ASH: American Society of Hematology
The treatment appeared to live up to its billing of having fewer off-target effects in studies presented at the American Society of Hematology.